BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced inducement grants for five newly-hired employees. The compensation package includes stock options to purchase 18,200 shares at $8.01 per share and restricted stock units (RSUs) covering 12,750 shares. Both options and RSUs will vest over four equal annual installments starting one year from the October 31, 2024 grant date. The stock options have a 10-year term, and all grants were made under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato concessioni di indennità per cinque nuovi assunti. Il pacchetto retributivo include opzioni su azioni per acquistare 18.200 azioni a $8,01 per azione e unità di azioni vincolate (RSU) per un totale di 12.750 azioni. Sia le opzioni che le RSU matureranno in quattro rate annuali uguali a partire da un anno dopo la data di concessione del 31 ottobre 2024. Le opzioni su azioni hanno una durata di 10 anni e tutte le concessioni sono state effettuate ai sensi della Regola di quotazione Nasdaq 5635(c)(4) come incentivi all'assunzione.
BioCryst Pharmaceuticals (Nasdaq: BCRX) anunció concesiones de inducimiento para cinco empleados recién contratados. El paquete de compensación incluye opciones sobre acciones para comprar 18,200 acciones a $8.01 por acción y unidades de acciones restringidas (RSUs) que cubren 12,750 acciones. Tanto las opciones como las RSUs se adquirirán en cuatro cuotas anuales iguales a partir de un año después de la fecha de concesión del 31 de octubre de 2024. Las opciones de acciones tienen un plazo de 10 años, y todas las concesiones se realizaron bajo la Regla de Cotización Nasdaq 5635(c)(4) como incentivos laborales.
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 새로 고용된 다섯 명의 직원에 대한 유도 보상을 발표했습니다. 보상 패키지에는 18,200주를 주당 $8.01에 구매할 수 있는 주식 옵션 및 12,750주를 포함하는 제한 주식 단위(RSU)가 포함되어 있습니다. 옵션과 RSU 모두 2024년 10월 31일 부여일로부터 1년 후에 시작하여 네 번의 동등한 연간 할부로 발생됩니다. 주식 옵션의 유효 기간은 10년이며, 모든 보상은 고용 유인으로서 Nasdaq 상장 규칙 5635(c)(4) 아래에서 이루어졌습니다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a annoncé des subventions d'incitation pour cinq nouveaux employés. Le package de rémunération comprend des options d'achat d'actions pour acquérir 18 200 actions à 8,01 $ chacune et des unités d'actions restreintes (RSUs) pour un total de 12 750 actions. Les options et les RSUs seront acquises en quatre versements annuels égaux à compter d'un an après la date d'octroi du 31 octobre 2024. Les options d'achat d'actions ont une durée de 10 ans, et toutes les subventions ont été accordées conformément à la règle de cotation Nasdaq 5635(c)(4) comme incitations à l'embauche.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat Anreizvergütungen für fünf neu eingestellte Mitarbeiter bekannt gegeben. Das Vergütungspaket umfasst Aktienoptionen zum Kauf von 18.200 Aktien zu einem Preis von 8,01 $ pro Aktie sowie eingeschränkte Aktieneinheiten (RSUs) für insgesamt 12.750 Aktien. Sowohl die Optionen als auch die RSUs werden in vier gleichen jährlichen Raten ab einem Jahr nach dem Zuteilungsdatum am 31. Oktober 2024 erworben. Die Aktienoptionen haben eine Laufzeit von 10 Jahren, und alle Zuteilungen wurden gemäß der Nasdaq-Notierungsregel 5635(c)(4) als Einstellungsanreize vorgenommen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
How many shares were granted in BioCryst's (BCRX) October 2024 inducement grants?
What is the exercise price for BCRX's October 2024 inducement stock options?
What is the vesting schedule for BCRX's October 2024 inducement grants?
